Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Exicure Inc (NQ: XCUR )

2.330 +0.020 (+0.87%)
Official Closing Price Updated: 7:35 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 345,800
Open 2.280
Bid (Size) 2.250 (4)
Ask (Size) 2.570 (1)
Prev. Close 2.310
Today's Range 2.230 - 2.350
52wk Range 0.9573 - 3.300
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Exicure Granted Two Fast Track Designations for Cavrotolimod (AST-008) from the U.S. Food and Drug Administration
Exicure announced that the U.S. FDA has granted Fast Track designations for cavrotolimod (AST-008) for two development programs. 
From Business Wire News Releases
Exicure Announces Appointment of James Sulat to Board of Directors
Exicure today announced the appointment of James Sulat to its Board of Directors. 
From Business Wire News Releases

Performance

YTD
+28.02%
+28.02%
1 Month
+20.73%
+20.73%
3 Month
+51.30%
+51.30%
6 Month
+2.64%
+2.64%
1 Year
-4.12%
-4.12%

More News

Read More
Exicure Announces Agenda for Upcoming Neuroscience Pipeline Update at Virtual R&D Day
From Business Wire News Releases
Exicure Announces Webcast of Presentation at 2021 HC Wainwright BIOCONNECT Conference
From Business Wire News Releases
Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day
From Business Wire News Releases
Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034
From Business Wire News Releases
Exicure to Participate in Upcoming Conferences
From Business Wire News Releases
Exicure, Inc. Reports Third Quarter 2020 Financial Results and Corporate Progress
From Business Wire News Releases
Exicure Presents Positive Clinical Data with Cavrotolimod at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
From Business Wire News Releases
Exicure Announces Phase 1b Poster Presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
From Business Wire News Releases
Exicure to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.